Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab + lenalidomide versus rituximab + gemcitabine + oxaliplatin in relapsed or refractory diffuse large B-cell lymphoma
NL-OMON59158Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epcoritamab, lenalidomide, rituximab, gemcitabine and oxaliplatin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Progression-free survival. Started Nov 2024; status: active, not recruiting.
02
Drugs
epcoritamablenalidomiderituximabgemcitabineoxaliplatin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NL-OMON59158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59158.